Wilson A, Kragh N, DiBenedetti D, Pan-Petesch B, Wynn T, Neme D, Willemze A. Patient experience with efanesoctocog alfa: results from the XTEND-1 phase 3 clinical trial exit interviews in patients with severe haemophilia A. Poster presented at the 16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023; February 7, 2023. Manchester, England. [abstract] Haematologica. 2023 Feb 5; 29(S1):137-8. doi: 10.1111/hae.14715
Twiss J, McKenna S, Crawford S, Wilburn J, Loth K. Are transfusions for Myelodysplasia (MDS) an acceptable treatment to patients? Poster presented at the 17th Congress of European Hematology Association; June 2012. Amsterdam, the Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(S1):693.
McKenna S, Twiss J, Wilburn J, Crawford S, Loth K. Investigation of the impact of MDS from the patients' perspective. Poster presented at the 17th Congress of the European Hematology Association; June 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jun; 97(S1):357-8.
Greene BL, Brown TM, Miller JD, Harshman R, Richerson G, Doyle JJ. Economic impact of the BP downshift program on blood pressure control among commercial driver license employees. Poster presented at the 2008 Academy of Managed Care Pharmacy Educational Conference; October 2008. [abstract] Am J Manag Care. 2008 Oct; 14(7).
Hadker N, Greene B, Brown TM, Harshman R, Richerson G, Turner B. Impact of the BP downshift program on blood pressure control among commercial driver's license employees: a managed care perspective. Am J Manag Care. 2007 Mar;13(2).